An NBER working paper by Barwick, Xia and Xia (2026) provides the answer: In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume…We provide strong evidence that China’s rise was primarily driven by the National Reimbursement Drug List (NRDL) reform,…
Mass General Brigham evaluates AI tools by carefully monitoring real-world performance before scaling them system-wide. At HIMSS earlier this month, Rebecca Mishuris, the health system’s chief health information officer and vice president of digital, explained what this process looks like. The post How Mass General Brigham Decides Which AI Tools Are Worth Scaling appeared first…
An Urban Institute report finds that the One Big Beautiful Bill Act could cause 5–10 million people to lose Medicaid coverage by 2028, with outcomes heavily dependent on how states implement work requirements and eligibility rules. The post State Mitigation Strategies Could Blunt Medicaid Coverage Losses appeared first on MedCity News.
Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing activity amid market turbulence from tariffs and war. The post Kailera Plans IPO for Obesity Drug That…
Fujifilm went from being the no. 1 camera film company to seeing sales tumble as consumers switched to digital cameras. Lars Petersen, CEO of the company’s biotechnologies business, explains how the company pivoted to becoming a partner of the life sciences industry. The post MedCity Pivot Podcast: How Fujifilm Tackled An Existential Crisis appeared first…
[Sponsored] If you’ve been researching current high-paying jobs in trauma centers or wondering which agencies have the best-paying contracts right now, you’re already thinking like a strategic travel nurse. The post Top-Paying Healthcare Settings for Travel Nurses and How to Land Them appeared first on MedCity News.
Rather than using AI to compete, we must design AI to collaborate. As the regulatory landscape evolves and industry pledges push for real-time, electronic, and transparent authorizations, the imperative is clear: technology must bridge the payer-provider divide, not widen it. The post AI Is Fueling a New Arms Race in Healthcare: Here’s How We Stop…
For consumers and clinicians the difference between “FDA-cleared,” “FDA-registered,” and general wellness products is not always obvious. Clear communication about intended use and supporting evidence is essential for maintaining trust. The post Red Light Therapy’s Regulatory Implications appeared first on MedCity News.
While CREST-2 can stand as a guideline for understanding ACS therapies in case-by-case scenarios, it’s critical that trial conclusions do not replace clinical judgment and years of previous research. The post Why CREST-2 Trial Results Should Inform, Not Replace, Clinical Judgment appeared first on MedCity News.
In 2013, a scientist at Abbott Laboratories saw study results with potentially big implications for the company’s profits and the lives of some of the world’s most fragile people: preterm infants. The upshot, she wrote in an email: Babies fed rival Mead Johnson Nutrition’s acidified liquid human milk fortifier — a nutritional supplement used in…